Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Costs associated with cardiovascular events in patients with hypertension in US managed care settings.

Duh MS, Fulcher NM, White LA, Jayawant SS, Ramamurthy P, Moyneur E, Ong SH.

J Am Soc Hypertens. 2009 Nov-Dec;3(6):403-15. doi: 10.1016/j.jash.2009.09.001.

PMID:
20409983
2.

Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.

Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

Am J Manag Care. 2002 Oct;8(15 Suppl):S414-27.

3.

Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors.

Amin AN, Jhaveri M, Lin J.

Adv Ther. 2011 Oct;28(10):907-26. doi: 10.1007/s12325-011-0065-6. Epub 2011 Sep 30.

PMID:
21971681
4.

Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.

Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

Appl Health Econ Health Policy. 2011 Sep 1;9(5):293-303. doi: 10.2165/11592430-000000000-00000.

PMID:
21875160
5.

Economic burden of cardiovascular events and fractures among patients with end-stage renal disease.

Doan QV, Gleeson M, Kim J, Borker R, Griffiths R, Dubois RW.

Curr Med Res Opin. 2007 Jul;23(7):1561-9.

PMID:
17555611
6.

Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting.

Straka RJ, Liu LZ, Girase PS, DeLorenzo A, Chapman RH.

Cardiovasc Diabetol. 2009 Sep 26;8:53. doi: 10.1186/1475-2840-8-53.

7.

Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed.

Boccuzzi SJ, Martin J, Stephenson J, Kreilick C, Fernandes J, Beaulieu J, Hauch O, Kim J.

Curr Med Res Opin. 2009 Dec;25(12):2853-64. doi: 10.1185/03007990903196422.

PMID:
19916729
8.

Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population.

Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

Appl Health Econ Health Policy. 2011 Nov 1;9(6):377-87. doi: 10.2165/11592440-000000000-00000.

PMID:
21888449
10.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
11.

Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective.

Straka RJ, Mamdani M, Damen J, Kuntze CE, Liu LZ, Botteman MF, Koren MJ.

Curr Med Res Opin. 2007 Jul;23(7):1517-29.

PMID:
17535539
12.

Cost estimation of cardiovascular disease events in the US.

O'Sullivan AK, Rubin J, Nyambose J, Kuznik A, Cohen DJ, Thompson D.

Pharmacoeconomics. 2011 Aug;29(8):693-704. doi: 10.2165/11584620-000000000-00000.

PMID:
21585226
13.

Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.

Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

Am J Manag Care. 2002 Oct;8(15 Suppl):S401-13.

14.

Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States.

Naccarelli GV, Johnston SS, Lin J, Patel PP, Schulman KL.

Clin Cardiol. 2010 May;33(5):270-9. doi: 10.1002/clc.20759.

15.

A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.

Gómez-Gerique JA, Casciano R, Stern L, Rejas J.

Eur J Health Econ. 2004 Oct;5(3):278-84.

PMID:
15714350
16.

Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.

Pike C, Birnbaum HG, Schiller M, Sharma H, Burge R, Edgell ET.

Pharmacoeconomics. 2010;28(5):395-409. doi: 10.2165/11531040-000000000-00000.

PMID:
20402541
17.

The burden of illness of hypertension and comorbid diabetes.

Eaddy MT, Shah M, Lunacsek O, Stanford RH.

Curr Med Res Opin. 2008 Sep;24(9):2501-7. doi: 10.1185/03007990802297529 . Epub 2008 Jul 29.

PMID:
18671895
19.

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes.

Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, Chen R, Wolf R, Mahaffey KW.

Postgrad Med. 2010 May;122(3):16-27. doi: 10.3810/pgm.2010.05.2138.

PMID:
20463410
20.

Characteristics and baseline clinical predictors of future fatal versus nonfatal coronary heart disease events in older adults: the Cardiovascular Health Study.

Pearte CA, Furberg CD, O'Meara ES, Psaty BM, Kuller L, Powe NR, Manolio T.

Circulation. 2006 May 9;113(18):2177-85. Epub 2006 May 1.

Supplemental Content

Support Center